Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

OSE Immunotherapeutics — 9 videos in collection

More on this equity

OSE Immunotherapeutics (OSE) is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharmaceutical companies. These therapies address numerous different indications and include Tedopi, OSE-127 and OSE-279.

In this interview, CEO Dr Nicolas Poirier provides highlights of the key therapies in development for both immuno-oncology and immuno-inflammation, including:

  • the preparation for a confirmatory pivotal Phase III trial for OSE’s lead asset Tedopi in non-small cell lung cancer;
  • the ongoing Phase I/II dose-escalation trial of OSE-279, an anti-PD1 monoclonal antibody ICI therapy designed for blockade of both PD-L1 and PD-L2; and
  • the ongoing Phase II clinical trial of Lusvertikimab, OSE’s most advanced immuno-inflammation asset.
< Previous
Next >

You may also be interested in these:

Healthcare

OSE Immunotherapeutics – equity proposition

Healthcare

OSE Immunotherapeutics – KOL event: Tedopi, most advanced therapeutic cancer vaccine
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.